Fierce Pharma Biopharma News & Insights
4 天之前 · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Pharma | Fierce Pharma
2024年10月14日 · The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
2024年4月15日 · There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five …
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's …
2025年1月17日 · As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion deal for the Chinese biopharma's phase 1 T …
'The Top Line': A look at pharma revenue rankings
2024年4月26日 · Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma …
2024 approvals: Biopharma delivered 55 new drugs, biologics
2025年1月2日 · The FDA signed off on 55 new drugs in 2024, down from 60-plus in 2023.
Fierce 50 of 2024 | Fierce Pharma
2024年9月9日 · I’m honored to introduce the second edition of the Fierce 50, where we once again spotlight the innovators and leaders driving the future of healthcare, pharma and …
About Us - Fierce Pharma
Biopharma is a fast-growing world where big ideas come along daily. Our readers rely on Fierce Pharma for the latest news, analysis and data on drugs and the companies that make them.
Fierce Pharma Asia—Takeda's $300M deal; Lonza's plant closure; …
2024年2月2日 · Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies. …
Asia - Fierce Pharma
2025年1月2日 · Takeda's R&D chief explained his new investment priorities. AZ and Daiichi's TROP2 ADC cleared the FDA. Fosun failed to buy out Henlius. And more.